Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Dr Gaia Coppock comments on how collaborative care among nephrologists is transforming glomerular disease treatment.

Dr Gaia Coppock examines approaches to guide colleagues and patients through the quickly changing landscape of IgA ...

The BCACC is pleased to announce the expansion of the 'Connection to Care' program to the BC Forest Safety Council (BCFSC). Starting today, BCFSC workers can access 'Connection to Care' - a ...

FORTÉ, formerly AVI Systems, today announced a series of executive leadership promotions that strengthen the company's operational, financial, innovation, marketing, and people-focused capabilities as ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, ...

Boston Scientific Corporation tops the list with its strong position in the medical device market. The company’s cardiovascular, rhythm management, and endoscopy product lines have positioned it as a ...

Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

As of Wednesday, December 24, Travere Therapeutics, Inc.’s TVTX share price has surged by 17.75%, which has investors questioning if this is right time to sell.

Travere Therapeutics (TVTX) just hit a fresh 52 week high after the FDA removed an advisory committee review and relaxed REMS monitoring for FILSPARI, sharpening focus on January’s FSGS approval ...

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.

Browse investing articles and stock analysis by Eric Volkman. Get expert financial insights and investment advice from The Motley Fool.